Cognition Therapeutics, Inc.
CGTX
$2.71
-$0.475-14.94%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.50M | 2.99M | 2.57M | 3.07M | 3.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.98M | 13.78M | 10.72M | 14.46M | 14.68M |
| Operating Income | -13.98M | -13.78M | -10.72M | -14.46M | -14.68M |
| Income Before Tax | -6.73M | -8.48M | -7.84M | -9.94M | -7.04M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.73M | -8.48M | -7.84M | -9.94M | -7.04M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.73M | -8.48M | -7.84M | -9.94M | -7.04M |
| EBIT | -13.98M | -13.78M | -10.72M | -14.46M | -14.68M |
| EBITDA | -13.96M | -13.75M | -10.70M | -14.44M | -14.65M |
| EPS Basic | -0.11 | -0.14 | -0.18 | -0.25 | -0.18 |
| Normalized Basic EPS | -0.07 | -0.09 | -0.11 | -0.15 | -0.11 |
| EPS Diluted | -0.11 | -0.14 | -0.18 | -0.25 | -0.18 |
| Normalized Diluted EPS | -0.07 | -0.09 | -0.11 | -0.15 | -0.11 |
| Average Basic Shares Outstanding | 63.69M | 61.83M | 44.68M | 40.42M | 40.06M |
| Average Diluted Shares Outstanding | 63.69M | 61.83M | 44.68M | 40.42M | 40.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |